NCT07570472 The Effect of CBD on Sleep Quality Following Late Evening Exercise
| NCT ID | NCT07570472 |
| Status | Recruiting |
| Phase | Phase 2 |
| Sponsor | KU Leuven |
| Condition | Sleep Quality |
| Study Type | INTERVENTIONAL |
| Enrollment | 20 participants |
| Start Date | 2026-03-19 |
| Primary Completion | 2026-05-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
In Phase 2, researchers evaluate early signs of effectiveness. You may be randomized to receive the active treatment or a comparator. Monitoring continues closely.
This trial targets 20 participants in total. It began in 2026-03-19 with a primary completion date of 2026-05-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The trial is a double-blind, placebo-controlled crossover design. In a randomized order, 20 participants undergo one control and two experimental sessions separated by a 1-week wash out period. During the no exercise/rest session, participants' sleep is monitored via polysomnography following a rest day. During the training sessions participants' sleep is monitored following a high intensity interval training (HIIT) in the late evening (finishing 1h prior to bedtime). During these sessions participants receive 2x 200mg CBD or placebo in a randomized order.
Eligibility Criteria
Inclusion Criteria: 1. Voluntary written informed consent of the participant or their legally authorized representative has been obtained prior to any screening procedures 2. Use of highly effective methods of birth control during the entire trial and for up to 4 months after the last dose of CBD; defined as those that, alone or in combination, result in low failure rate (i.e., less than 1% per year) when used consistently and correctly; such as implants, injectables, combined oral contraceptives, some IUDs, true sexual abstinence (i.e. refraining from heterosexual intercourse during the entire period of risk associated with the Trial treatment(s)) or commitment to a vasectomised partner. 3. Age between 18-40 years old at the time of signing the Informed Consent Form (ICF) 4. Recreationally active (between 2-8h/wk) 5. Good health status confirmed by a sport medical screening 6. Body fat percentage below 20% (males) or 25% (females) as estimated by a Dual-energy X-ray absorptiometry (DXA) scan 7. Good sleep efficiency determined by the Pittsburgh Sleep Quality Index (PSQI, score ≤ 4) Exclusion Criteria: 1. Self-reported sleep disturbances 2. Habitual smoking (\> 1 occasion/month) 3. Any kind of injury/incapability that is a contra-indication to perform high intensity interval training 4. Female who is pregnant, breast-feeding or intends to become pregnant or is of child-bearing potential and not using an adequate, highly effective contraceptive. A woman is considered of childbearing potential (WOCBP), i.e. fertile, following menarche and until becoming post menopausal unless permanently sterile. Permanent sterilisation methods include hysterectomy, bilateral salpingectomy and bilateral oophorectomy. 5. Participation in another interventional Trial with an investigational medicinal product (IMP) or device 6. Use of CBD related products 3 months prior to the start of the experimental trial (including CBD oil, cannabis or other substances containing cannabinoids) 7. Intake of any medication or nutritional supplement that influences sleep quality 3 months prior to the start of the experimental trial 8. Shift workers or extreme morning and evening chronotypes (scores between 16-30 or 70-86 on the Morningness-Eveningness Questionnaire (MEQ))
Frequently Asked Questions
Who can join the NCT07570472 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 40 Years, studying Sleep Quality. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
What phase is the NCT07570472 trial and what does that mean for participants?
Phase 2 trials evaluate whether the treatment shows signs of effectiveness while continuing to monitor safety. More participants are enrolled than in Phase 1 to help refine the treatment protocol.
Is NCT07570472 currently recruiting?
Yes, NCT07570472 is actively recruiting participants. Visit ClinicalTrials.gov or contact KU Leuven to inquire about joining.
Where is the NCT07570472 trial being conducted?
This trial is being conducted at Leuven, Belgium.
Who is sponsoring the NCT07570472 clinical trial?
NCT07570472 is sponsored by KU Leuven. The trial plans to enroll 20 participants.